Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in Myelodysplastic Syndrome After Azacitidine Failure (DEC-MDS)
2009-017098-40Phase 2Terminated
- Sponsor
- King's College London
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by King's College London. Primary endpoint: Overall response rate at 6 months. Started Jun 2010; status: terminated.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-017098-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017098-40.